Prevalence of autosomal dominant polycystic kidney disease in Persian and Persian-related cats in Brazil / Prevalência da doença renal policística autossômica dominante em gatos Persas e raças relacionadas no Brasil

Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic disease in cats. However, scarce data on its prevalence are available in Brazil. Persian cats and Persian-related breeds were assessed by molecular genotyping for a C to A transversion in exon 29 of PKD1 gene to determine ADPKD prevalence in a Brazilian population. Genomic DNA extracted from peripheral whole blood or oral swabs samples was used to amplify exon 29 of PKD1 gene employing a PCR-RFLP methodology. From a total of 616 animals, 27/537 Persian and 1/17 Himalayan cats showed the single-nucleotide variant (C to A) at position 3284 in exon 29 of feline PKD1. This pathogenic variation has been identified only in heterozygous state. The prevalence of ADPKD in Persian cats and Persian-related breeds was 5.03% and 1.6%, respectively. There was no significant association between feline breed, gender or age with ADPKD prevalence. Of note, the observed ADPKD prevalence in Persian cats and Persian-related breeds in Brazil was lower than the ones reported in other parts of the world. This finding may be related to genetic counseling and consequent selection of ADPKD-free cats for reproduction.

A doença renal policística autossômica dominante (DRPAD) é a doença genética mais comum em gatos. No entanto, poucos dados sobre sua prevalência estão disponíveis no Brasil. Gatos Persas e de raças relacionadas foram avaliados por genotipagem molecular para a transversão C→A no exon 29 do gene PKD1 felino para determinar a prevalência de DRPAD. DNA genômico extraído de sangue total periférico ou amostras de swabs orais foram utilizados para amplificar o exon 29 do gene PKD1 pela técnica de PCR-RFLP. De um total de 616 gatos, 27/537 Persas e 1/17 Himalaia mostraram a variante de nucleotídeo único (C→A) na posição 3284 no exon 29 do gene PKD1. Esta variante patogênica foi identificada apenas em heterozigose. A prevalência de DRPAD em gatos Persas e raças relacionadas foram de 5,03% e 1,6%, respectivamente. Não houve associações significativas entre raça, gênero ou idade dos felinos e incidência de DRPAD. A prevalência de DRPAD em gatos Persas e raças relacionadas no Brasil foi menor do que em outras partes do mundo, o que pode estar relacionado ao aconselhamento genético e consequente seleção de gatos sem ADPKD para reprodução.

Identification of a novel UMOD mutation (c. 163G>A) in a Brazilian family with autosomal dominant tubulointerstitial kidney disease

Autosomal dominant tubulointerstitial kidney disease (ADTKD) is characterized by autosomal dominant inheritance, progressive chronic kidney disease, and a bland urinary sediment. ADTKD is most commonly caused by mutations in the UMOD gene encoding uromodulin (ADTKD-UMOD). We herein report the first confirmed case of a multi-generational Brazilian family with ADTKD-UMOD, caused by a novel heterozygous mutation (c.163G>A, GGC→AGC, p.Gly55Ser) in the UMOD gene. Of 41 family members, 22 underwent genetic analysis, with 11 individuals found to have this mutation. Three affected individuals underwent hemodialysis, one peritoneal dialysis, and one patient received a kidney transplant from a family member later found to be genetically affected. Several younger individuals affected with the mutation were also identified. Clinical characteristics included a bland urinary sediment in all tested individuals and a kidney biopsy in one individual showing tubulointerstitial fibrosis. Unlike most other reported families with ADTKD-UMOD, neither gout nor hyperuricemia was found in affected individuals. In summary, we report a novel UMOD mutation in a Brazilian family with 11 affected members, and we discuss the importance of performing genetic testing in families with inherited kidney disease of unknown cause.

Polycystin-1 C terminus cleavage and its relation with polycystin-2, two proteins involved in polycystic kidney disease / Clivaje del C-terminal de policistina-1 y su relación con policistina-2, dos proteínas involucradas en la poliquistosis renal

Autosomal dominant polycystic kidney disease (ADPKD), a most common genetic cause of chronic renal failure, is characterized by the progressive development and enlargement of cysts in kidneys and other organs. The cystogenic process is highly complex and involves a high proliferative rate, increased apoptosis, altered protein sorting, changed secretory characteristics, and disorganization of the extracellular matrix. ADPKD is caused by mutations in the genes encoding polycystin-1 (PC-1) or polycystin-2 (PC-2). PC-1 undergoes multiple cleavages that intervene in several signaling pathways involved in cellular proliferation and differentiation mechanisms. One of these cleavages releases the cytoplasmic C-terminal tail of PC-1. In addition, the C-terminal cytoplasmic tails of PC-1 and PC-2 interact in vitro and in vivo. The purpose of this review is to summarize recent literature that suggests that PC-1 and PC-2 may function through a common signaling pathway necessary for normal tubulogenesis. We hope that a better understanding of PC-1 and PC-2 protein function will lead to progress in diagnosis and treatment for ADPKD.

La poliquistosis renal autosómica dominante (ADPKD por sus siglas en inglés) es una causa genética muy común de falla renal crónica que se caracteriza por el progresivo desarrollo y agrandamiento de quistes en los riñones y en otros órganos. El proceso de cistogénesis comprende incrementos en la proliferación y muerte celular por apoptosis, así como alteraciones en la distribución intracelular de proteínas, el movimiento transcelular de solutos y organización de la matriz extracelular. ADPKD es causada por mutaciones en los genes que codifican para policistina-1 (PC-1) o policistina-2 (PC-2). PC-1 puede sufrir múltiples clivajes y los fragmentos generados intervienen en diferentes cascadas de señalización involucradas en mecanismos de proliferación y diferenciación celular. Uno de estos clivajes libera el extremo C-terminal citoplasmático de la PC-1. Se ha demostrado que los extremos C-terminal citoplasmático de PC-1 y PC-2 pueden interactuar tanto in vitro como in vivo. El propósito de esta revisión es resumir la literatura más reciente que sugiere que PC-1 y PC-2 pueden funcionar a través de una cascada de señalización común necesaria para la tubulogénesis normal. Creemos que una mejor comprensión de los mecanismos moleculares de acción de PC-1 y PC-2 contribuirán al progreso en el diagnóstico y tratamiento de ADPKD.

Molecular and cellular pathogenesis of autosomal dominant polycystic kidney disease

Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common human life-threatening monogenic disorders. The disease is characterized by bilateral, progressive renal cystogenesis and cyst and kidney enlargement, often leading to end-stage renal disease, and may include extrarenal manifestations. ADPKD is caused by mutation in one of two genes, PKD1 and PKD2, which encode polycystin-1 (PC1) and polycystin-2 (PC2), respectively. PC2 is a non-selective cation channel permeable to Ca2+, while PC1 is thought to function as a membrane receptor. The cyst cell phenotype includes increased proliferation and apoptosis, dedifferentiation, defective planar polarity, and a secretory pattern associated with extracellular matrix remodeling. The two-hit model for cyst formation has been recently extended by the demonstration that early gene inactivation leads to rapid and diffuse development of renal cysts, while inactivation in adult life is followed by focal and late cyst formation. Renal ischemia/reperfusion, however, can function as a third hit, triggering rapid cyst development in kidneys with Pkd1 inactivation induced in adult life. The PC1-PC2 complex behaves as a sensor in the primary cilium, mediating signal transduction via Ca2+ signaling. The intracellular Ca2+ homeostasis is impaired in ADPKD, being apparently responsible for the cAMP accumulation and abnormal cell proliferative response to cAMP. Activated mammalian target for rapamycin (mTOR) and cell cycle dysregulation are also significant features of PKD. Based on the identification of pathways altered in PKD, a large number of preclinical studies have been performed and are underway, providing a basis for clinical trials in ADPKD and helping the design of future trials.

Tratamientos específicos en poliquistosis renal autosómica dominante: una biología compleja y una enfermedad de larga duración / Specific treatments for autosomal dominant polycystic kidney disease: a complex biology and a long duration disease

ADPKD es ocasionada por mutaciones en los genes PKD1 y PKD2. Sus dos proteínas, las policistinas 1 y 2, asientan en el cilium primario inmóvil de cada célula y contribuyen a través de su función mecanosensora a una señalización normal del calcio intracelular (Ca2+). Los quistes renales crecen por un doble proceso epitelial, secreción aumentada de fluidos y mayor proliferación, productos del aumento del AMPc intracelular. En esta línea de hallazgos, se demostró en animales que el uso de un inhibidor del receptor V2(OPC-31260) de la vasopresina endógena disminuye el aumento del volumen renal y de los quistes y preserva el filtrado glomerular (FG). Por otro lado, la inhibición de la proteína kinasa mTOR (mamalian target of rapamycin), que regula múltiples funciones celulares e integra la información que llega de vías que incluyen la insulina, factores de crecimiento y mitógenos, también se demostró efectiva en modelos animales. En base a estos datos se inició un ensayo clínico en fase III (Estudio TEMPO) con el inhibidor OPC-31260 (Tolvaptan) del receptor V2 de la vasopresina. No existen todavía datos preliminares de su influencia sobre el crecimiento del volumen renal y el FG, pero disminuye la reabsorción de agua libre y causa diabetes insípida nefrogénica parcial por su acción sobre el receptor V2. Enfoques similares sobre la inhibición del contenido de AMPc intracelular pueden lograrse en humanos con la somatostina y su análogo de acción prolongada octeotride. Los estudios en humanos con inhibidores de mTOR (everolimus y sirolimus) mostraron disminución del volumen renal pero con mayor declinación del FG en el primer caso y no diferencias en esos índices en el segundo. En conclusión, si bien los modelos animales han provisto un enfoque racional para los ensayos clínicos en humanos, son necesarios nuevos protocolos que estimen cuándo comenzar el tratamiento, cómo evaluar la etapa biológica de la enfermedad y qué marcadores de eficacia son necesarios en una enfermedad de larga duración como ADPKD.

[Association analysis of autosomal dominant polycystic kidney disease in familial type in East-Azerbaijan]

Familial form of polycystic kidney disease which is inherited as an autosomal dominant pattern is one of the most common form of kidney disease. The main manifestation of this disease is the presence of growing cysts in kidney which results in malfunction of kidney. The frequency of disease is one in 1000 living birth. Mutation in one of the three different genes could result in developing polycystic kidney disease. Genetically analysis has been able to identify two of the genes, PKD1 and PKD2, located on chromosome 16 and chromosome 4 respectively. The location of the third gene remains unrevealed and the frequency of families affected due to the mutation on this gene is very low. By applying microsatellites tightly linked to the identified polycystic kidney disease genes, affected families referred from East Azerbaijan were genetically analyzed. Families with at least three affected members by polycystic kidney disease were studied. Polymorphic microsatellites from the regions of PKD1 and PKD2 were selected by studying the members of these families. All members of the families were investigated by the polymorphic markers to study linkage analysis. Out of 13 families with 99 members referred by specialists, 7 families with 75 members were selected on the base of availability. Disease in three of these families showed linkage with PKD2 gene and in one family linkage was found between the disease and PKD1 gene. In another family linkage was observed with neither PKD1 nor PKD2 genes. None of the markers were informative in two of the families; therefore these families were excluded from the studies. Most of the families with polycystic kidney disease from North West of Iran, showed linkage with PKD2 gene. One of the families did not show linkage with any of the known genes. In this family, disease could be due to mutation in the third gene which remains to be identified

Progresión de la poliquistosis renal autosómica dominante. Influencia de polimorfismos de genes de sintasa endotelial del óxido nítrico (ecNOS) y del sistema renina-angiotensina / Progression of autosomic dominant polycystic kidney disease. Influence of endothelial NO synthase (ecNOS) and renin angiotensin system gene polymorphisms

Glomerular filtration rate decline (GFRd) is variable in autosomic dominant polycystic kidney disease (ADPKD). In 88 ADPKD patients, GFRd was assessed by 1/S(Cr) and compared with the association to AT1A1166C (AT1R), AGTM235T (angiotensinogen) and ecNOSGlu298Asp (NO endothelial synthase) polymorphisms. Age at S(Cr) values of 2 and 6 mg/dl were assumed as beginning of progressive phase (A2) and end-stage-renal disease (A6), respectively. Polymorphisms were studied by PCR-RFLP. The group as a whole showed GFRd (ml/min/year) of 6.9+/-0.5; A2 and A6 of 48.9+/-1.3 and 55.0+/-1.4 years and mean arterial pressure of 111.2+/-1.2 mmHg. When A6 was considered, two populations were defined (< or = and > 55 years). In < or = 55 (assumed as PKD1 phenotype) (n=42), A2 and A6 of the AT1 1166CC genotype were 36.0+/-1.2 and 41.4+/-0.9 years vs AA-AC (42.8+/-1.0 and 47.5+/-0.8, p<0.001). A2 and A6 of the ecNOS298Asp/Asp genotype were 34.8+/-1.5 and 41.1+/-0.6 years vs. Glu/Glu-Glu/Asp (42.4+/-0.9 and 47.1+/-0.8, p<0.02). In AGT235TT genotype, GFRd was 12.4+/-2.2 ml/min/year vs MM-MT (7.9+/-0.7, p<0.03). This difference was also observed when all ADPKD patients were considered (TT: 11.02+/-1.5 vs. MM-MT: 6.44+/-0.5 ml/ min/year, p<0.003). AT1 1166CC and ecNOS 298Asp/Asp are associated with earlier A2 and A6 whereas AGT 235TT induce twofold increase in GFRd, suggesting that RAS and ecNOS are involved in ADPKD progression.

La velocidad de progresión (VdP) de la poliquistosis renal autosómica dominante (PQRAD) es variable.Estudiamos la asociación de los polimorfismos AGTM235T (angiotensinógeno), AT1A1166C(ATR1) y ecNOSGlu298Asp (NO sintasa endotelial) con la VdP en 88 pacientes. VdP fue estimada por 1/Crplvs edad. Consideramos edades de Crpl 2 y 6 mg/dl como comienzo de progresión (E2) y arribo a insuficienciarenal crónica terminal (E6), respectivamente. Los polimorfismos se estudiaron por PCR-RFLP. El grupo en sutotalidad presentó VdP (ml/min/año) de 6.9±0.5, E2 y E6 de 48.9±1.3 y 55.0±1.4 años y tensión arterial media(TAM) de 111.2±1.2 mmHg. Según E6 observamos dos grupos (≤ y > a 55 años). En ≤ 55 (fenotipo PKD1,n=42), E2 y E6 del genotipo CC de AT1A1166C fueron 36.0±1.2 y 41.4±0.9 años vs. AA-AC (42.8±1.0 y 47.5±0.8, p < 0.001). E2 y E6 del genotipo ecNOS298Asp/Asp fueron 34.8±1.5 y 41.1±0.6 años vs. Glu/Glu-Glu/Asp (42.4±0.9 y 47.1±0.8, p < 0.02). En el genotipo AGT235TT, la VdP fue 12.4±2.2 ml/min/año vs. MM-MT (7.9±0.7, p < 0.03). Esta diferencia también se observó cuando analizamos todos los pacientes PQRAD (TT: 11.02±1.5 vs. MM-MT: 6.44±0.5 ml/min/año, p < 0.003). Los genotipos AT1 1166CC y ecNOS 298Asp/Asp anticipan E2 y E6 mientras que AGT235TT duplica VdP, sugiriendo la participación del sistema renina angiotensina y NO sintasaendotelial en la progresión de la PQRAD.

Desarrollo de un registro genético preventivo automatizado de una enfermedad autosómica dominante / Development of automated genetic preventive register of an autosomal dominant disease

Se presenta la metodología aplicada para el desarrollo de un registro genético preventivo para una enfermedad genética autosómica dominante, tomando como base la enfermedad poliquística renal autosómica dominante. Se describe el modelo de historia genética familiar diseñado, los métodos de acceso y seguimiento, así como el programa de computación creado para la automatización del registro, los cuales pudieran aplicarse en el estudio de otras enfermedades con características similares. Se exponen algunas aplicaciones y utilidades de este registro

Monitoring of molecular ans cytogenetic damage in lymphocytes from three persons with polycystic kidney disease

Background. Much interest has been generated in the studies that would help to under stand whether is a causal association between disease and various types of molecular or cytogenetic damage detected in human cells. Materials and Methods. The aims of this study were to elicit the possible association between DNA and cytogenetic damage induced in lymphocytes of three members of a family with autosomal dominant polycystic kidney disease (ADPKD). Ther predictability to develop cancer or to sensitive response to enviromental exposure of the young girl at the age of 19, her brother (9 years old) and a maternal aunt at the age of 41 were sought. Cytogenetic studies, analysis of DNA damage by single cell gel electrophoresis assay (SCGE known as a Comet assay), and analysis of p21ras protein level in blood plasma were carried out on their lymphocytes. Results. The analysis for presence of chromosome aberrations in the first mitosis and sister chromatid exchanges in the second mitosis revealed elevated levels of cytogenetic biomarkers when compared to the mean values observed in the reference group in environmental biological monitoring studies. Results of sister chromatid exchanges (SCE) and percent of cells with elevated number of exchanges (high frequency cells) that were significantly higher in two probands had demonstrated susceptibility to or possibility of enviromental exposure (pesticides, smoking). The results of this study show that the lymphocytes of two persons revealed increased sensitivity to 0.5 Gy dose of gamma radiation expressed in the increased, atthough statistically insignificant, damage detected on the molecular level after cell irradiation. Conclusions. The latter might be associated with a specific aberration present in the cells of these persons. But final conclusions can be arrived at when an application of FISH technique is completed

Poliquistosis renal autosomica dominante: deteccion de una nueva mutacion en el gen PKD1 / Autosomal dominant polycystic kidney disease: detection of a novel mutation in the PKD1 gene

La poliquistosis renal autosómica (ADPKD) es una enfermedad hereditaria que presenta heterogeneidad genética. Al menos tres genes son responsables del desarrollo de la enfermedad: PKD1 en el cromosoma 16p 13.3, PKD2 en 4q21 y PKD3, aún no localizado. A partir de la descripción de la secuencia del gen PKD1, el interés general se volcó a la búsqueda de mutaciones causantes de la enfermedad. La mayoría de las mutaciones halladas es de diverso origen y localiza a lo largo del gen, no pudiendo hallarse correlación fenotípica alguna. En este trabajo se describe el hallazgo de una mutación en el exón 44 del gen PKD1 en una familia previamente caracterizada por análisis de ligamiento. La mutación consiste en una sustitución de una base C por una T en la posición 12220 originado un codón stop donde se produce la mutación. Esto llevaría a una terminación prematura en la traducción produciendo una proteína en la cual estaría ausente parte del extremo carboxílico.

Enfermedad poliquística en una familia mexicana: revisión de la literatura / Polycystic disease in Mexican family: review of the literature

Los estudios genéticos de familias con enfermedad poliquística renal autosómica son escasos, no obstante que es una de las alteraciones hereditarias más frecuentes. Este padecimiento se debe a una mutación en el genoma del locus PKD1 localizado en el brazo corto del cromosoma 16. Esta alteración se ha calculado en una proporción de 1:1000. Se informa de seis pacientes pertenecientes a una familia mexicana studiada en un lapso de 45 años. Existe un periodo muy largo asintomático entre el principio del padecimiento y la etapa final. Después de los 30 años aumenta el diagnóstico de los quistes tanto en número como en tamaño. Para el diagnóstico, es de gran utilidad el ultrasonido como procedimiento fácil, económico y que emplea energía no ionizante. El tratamiento quirúrgico temprano de los quistes renales previene o retarda la etapa final de insuficiencia renal crónica.

Rim policistico autossomico dominante volumoso / Autosomic dominant polycystic kidneys

Homem de 48 anos com rins policisticos de carater autossomico dominante com dimensoes, ao que nos consta, nunca antes relatados, pesando o direito 15.100g e medindo 53x33x9 cm e o esquerdo 10.200g e 46x21x7 cm, apresentado cistos com ate 14 cm de diametro. Foi submetido a nefrectomia devido a hematuria persistente e desconforto causado pelo grande volume de rins, apresentando boa evolucao apos o transplante renal